Back to top
more

Owens & Minor (OMI)

(Delayed Data from NYSE)

$16.48 USD

16.48
1,898,347

+1.17 (7.64%)

Updated Jul 23, 2024 04:00 PM ET

After-Market: $16.48 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Omnicell (OMCL) Q1 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

Omnicell's (OMCL) raises adjusted EPS guidance for 2021 , which buoys optimism.

DexCom (DXCM) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

DexCom's (DXCM) first-quarter results benefit from domestic and international revenue growth.

Teleflex (TFX) Beats on Q1 Earnings and Revenues, Raises View

by Zacks Equity Research

The acquisition of Z-Medica and an increase in sales of new products contribute to Teleflex's (TFX) revenue growth in Americas in Q1

ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

ABIOMED's (ABMD) international and U.S. Impella revenues improve in Q4.

Surmodics (SRDX) Q2 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Surmodics (SRDX) records higher revenues in both its core units in the fiscal second quarter.

Is Owens & Minor (OMI) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

CONMED (CNMD) Earnings and Revenue Surpass Estimates in Q1

by Zacks Equity Research

CONMED (CNMD) witnesses growth in revenues in both its segments during Q1.

LabCorp (LH) Q1 Earnings Surpass Estimates, View Raised

by Zacks Equity Research

LabCorp's (LH) raises 2021 guidance but projects significant sinking of COVID-related testing revenues.

Hologic (HOLX) Q2 Earnings Miss Estimates, Margins Rise

by Zacks Equity Research

Hologic (HOLX) exhibited robust segmental growth in second-quarter fiscal 2021, driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.

Amedisys (AMED) Q1 Earnings Beat Estimates, 2021 View Up

by Zacks Equity Research

Amedisys' (AMED) first-quarter 2021 revenues improves year over year on solid growth in the Home Health and Hospice divisions.

OPKO Health (OPK) Q1 Earnings Match Estimates, Revenues Top

by Zacks Equity Research

OPKO Health's (OPK) first-quarter results benefit from strength in diagnostics.

Integra (IART) Q1 Earnings Beat Estimates, Gross Margin Down

by Zacks Equity Research

Integra's (IART) first-quarter revenues improved year over year on organic growth across Codman Specialty Surgical and Tissue Technologies segments.

Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Baxter's (BAX) first-quarter results reflect robust performance across five of its business units.

Align Technology (ALGN) Q1 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Align Technology's (ALGN) segments report solid Q1 sales across geographies despite the pandemic-led business challenges.

Owens & Minor (OMI) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Owens & Minor (OMI) closed at $36.84 in the latest trading session, marking a +0.16% move from the prior day.

Chemed (CHE) Q1 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

Chemed's (CHE) first-quarter 2021 revenues increase year-over-year on solid growth across its Roto-Rooter arm.

Accuray (ARAY) Posts Breakeven Q3 Earnings, Beats on Revenues

by Zacks Equity Research

Accuray (ARAY) registers growth in Service and Product revenues during fiscal Q3.

Owens & Minor (OMI) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Owens & Minor (OMI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Owens & Minor (OMI) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Owens & Minor (OMI) witnesses rebound in demand for elective procedures through the months of Q1.

Boston Scientific (BSX) Q1 Earnings Beat, Organic Sales Up

by Zacks Equity Research

Boston Scientific (BSX) registers strong sequential improvement in overall financial performance in Q1.

InMode (INMD) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

InMode's (INMD) Morpheus8 Platform and Morpheus8 Body that use RF fractional technology are expected to have continued to contribute to the company's Q1 top line.

Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Henry Schein's (HSIC) PPE sales from its medical business are likely to have maintained the momentum. Also, global recovery trends of its dental business are expected to aid Q1 results.

Is a Beat in the Cards for CVS Health (CVS) in Q1 Earnings?

by Zacks Equity Research

Given the increasing number of walk-in-clinical appointments and patient visits, CVS Health (CVS), which has a huge PBM client base, is expected to have seen a sequential rebound in Q1 revenues.

Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Zimmer Biomet's (ZBH) first-quarter 2021 revenues are likely to have been adversely impacted due to pandemic-led lower elective procedure volumes.

Penumbra (PEN) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Growth across vascular thrombectomy and embolization products is expected to have contributed to Penumbra's (PEN) Q1 performance.